Meros Investment Management LP Makes New $4.76 Billion Investment in AtriCure, Inc. $ATRC

Meros Investment Management LP bought a new position in shares of AtriCure, Inc. (NASDAQ:ATRC) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 170,000 shares of the medical device company’s stock, valued at approximately $4,756,600,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in shares of AtriCure by 1.0% in the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after buying an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in AtriCure by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after buying an additional 1,230 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in AtriCure by 1.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after acquiring an additional 8,956 shares during the last quarter. Jane Street Group LLC increased its position in AtriCure by 658.3% in the 1st quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock valued at $3,254,000 after acquiring an additional 87,553 shares in the last quarter. Finally, Strs Ohio acquired a new stake in AtriCure in the 1st quarter valued at about $158,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Price Performance

Shares of ATRC opened at $48.68 on Wednesday. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14. AtriCure, Inc. has a 1 year low of $25.36 and a 1 year high of $49.88. The stock has a market cap of $2.48 billion, a P/E ratio of 231.82 and a beta of 1.20. The stock’s 50-day moving average price is $36.67 and its two-hundred day moving average price is $31.97.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The company had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the prior year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts predict that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ATRC has been the subject of a number of research analyst reports. Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. UBS Group decreased their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Finally, Raymond James Financial set a $52.00 price objective on AtriCure in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, AtriCure currently has an average rating of “Moderate Buy” and an average price target of $48.62.

Insider Activity

In other news, insider Justin J. Noznesky sold 6,182 shares of AtriCure stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the transaction, the insider directly owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Vinayak Doraiswamy sold 6,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total transaction of $233,280.00. Following the completion of the transaction, the insider directly owned 86,511 shares of the company’s stock, valued at $3,363,547.68. This trade represents a 6.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 44,246 shares of company stock valued at $1,691,895. 4.00% of the stock is currently owned by company insiders.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.